Quick Answer
As of November 2026, no published paper and no registered trial has combined retatrutide with eloralintide. The nearest human evidence is Eli Lilly's phase 2 trial of eloralintide with tirzepatide, in which the top combination arm reached 23.3% mean weight loss at 48 weeks against 14.8% with tirzepatide alone, in adults with obesity or overweight and type 2 diabetes. Whether retatrutide and eloralintide interact, how well they are tolerated together and what ratio would make sense are all unknown.
Key facts
- Retatrutide (LY3437943) is one molecule that activates the GIP, GLP-1 and glucagon receptors. Eloralintide (LY3841136) is a selective amylin receptor agonist. Both are investigational compounds from Eli Lilly.
- Checked in November 2026: PubMed has no study of the two together, and ClinicalTrials.gov lists no trial that includes both.
- Eloralintide with tirzepatide, phase 2, 367 adults with type 2 diabetes, 48 weeks: up to 23.3% weight loss, against 14.8% with tirzepatide alone and 3.0% with placebo (company figures, not yet peer reviewed).
- Cagrilintide with semaglutide, REDEFINE 1, phase 3, 68 weeks: 20.4% against 3.0% with placebo.
- Retatrutide alone, TRIUMPH-1, phase 3, 80 weeks: 17.6% to 25.0% against 3.9% with placebo.
- Eloralintide alone, phase 2, 48 weeks: about 9% to 20% against 0.4% with placebo.
- The only published test of retatrutide with any amylin compound used cagrilintide, in male rats.
People search for these two compounds "together" far more often than the research record can answer. Our eloralintide vs retatrutide comparison sets the two side by side. This article takes the other question: what is known about using them as a pair. The short version is that the pair itself is unstudied, and everything else is evidence from neighbouring combinations.
Has anyone studied retatrutide and eloralintide together?
No. We searched PubMed and ClinicalTrials.gov in November 2026. PubMed returned one paper that mentions both names, a review of obesity drug classes that discusses them separately and reports no combination. A registry search for trials listing both returned nothing. Of the 22 registered studies that involve eloralintide, none lists retatrutide, and none of the registered retatrutide studies lists eloralintide or any other amylin compound.
That is notable because both compounds belong to the same company. Lilly has chosen tirzepatide, not retatrutide, as eloralintide's partner in its own trials. So there is no efficacy figure, no tolerability record and no tested ratio for retatrutide with eloralintide, in people or in animals.
What is each compound on its own?
Retatrutide is a single peptide that activates three receptors: GIP, GLP-1 and glucagon. The discovery paper reported that in obese mice it lowered body weight through reduced food intake plus a rise in energy expenditure linked to the glucagon receptor (Coskun et al., 2022). In a 48-week phase 2 trial of 338 adults with obesity, mean weight loss reached 24.2% in the top group against 2.1% with placebo (Jastreboff et al., 2023). The phase 3 TRIUMPH-1 trial randomised 2,339 adults with obesity and without diabetes for 80 weeks: weight fell by 17.6%, 23.7% and 25.0% in the three retatrutide groups against 3.9% with placebo, counting everyone randomised (Jastreboff et al., 2026). Gastrointestinal events were the most common side effects. More background is on our retatrutide page.
Eloralintide is a long-acting amylin receptor agonist built to favour the amylin 1 receptor. In cell assays it activated that receptor about 12 times more potently than the calcitonin receptor, and in rats it reduced food intake and body weight, mainly through fat loss (Briere et al., 2025). In a 48-week phase 2 trial of 263 adults with obesity or overweight and without type 2 diabetes, weight fell by about 9% to 20% across the eloralintide groups against 0.4% with placebo, on an analysis that assumes participants stayed on treatment. Nausea and fatigue were the most common side effects (Billings et al., 2025). Our eloralintide research overview covers it in full.
Why would amylin activity be added to incretin activity?
Both families reduce eating, but through different receptors. Amylin is released from the pancreas with insulin and acts principally in the brain's circumventricular organs, structures outside the blood-brain barrier that include the area postrema in the brainstem (Hay et al., 2015). That review noted that amylin agonists might be most useful for weight loss in combination with other agents.
Rat work supports the idea that the routes are partly separate. The longer-term effects of the amylin compound cagrilintide ran through brainstem neurons that make prolactin-releasing hormone, and reducing that hormone blocked the effects of cagrilintide but not those of the GLP-1 compound semaglutide (Ludwig et al., 2026). A 2026 review describes amylin compounds as working through pharmacological and neural mechanisms distinct from incretin-based ones (Fischer and Borner, 2026).
On paper, then, retatrutide with eloralintide would cover four receptor systems. That is a hypothesis about this pair, not a finding.
What did eloralintide with tirzepatide show?
This is the nearest human evidence. Lilly's phase 2 trial (NCT06603571) randomised 367 adults with obesity or overweight and type 2 diabetes, in the US and Argentina, for 48 weeks. Lilly reported the results on 30 September 2026, alongside a presentation at the EASD meeting in Milan (Eli Lilly, 30 September 2026). Mean weight change by group:
- Combination, four groups: 13.2%, 19.4%, 19.9% and 23.3%.
- Tirzepatide alone: 14.8%.
- Eloralintide alone, three groups: 8.2%, 12.3% and 11.1%.
- Placebo: 3.0%.
HbA1c fell by 2.2 to 2.9 percentage points with the combination, against 2.4 with tirzepatide alone and 0.3 with placebo, from a baseline of 8.1%. These figures assume participants stayed on treatment, which gives larger numbers than counting everyone randomised.
The cost was tolerability. Gastrointestinal events were more frequent with the combination than with either compound alone, and 10.8% to 27.0% of the combination groups stopped treatment because of side effects, against 2.9% on tirzepatide alone and 16.7% on placebo.
The same data were scheduled for an oral session at ObesityWeek on 15 November 2026. In its release ahead of the meeting, Lilly added that up to 77% of participants reached normal blood sugar levels and up to 60% no longer met the BMI criteria for obesity (Eli Lilly, 14 November 2026). As of November 2026 the trial has not been published in a journal.
In phase 2 the two compounds were given separately. Lilly said it would start phase 3 trials of a single co-formulated product by the end of 2026, and two are now registered: AMPLIFY-2 in adults with type 2 diabetes, recruiting since October 2026 (NCT07881458), and AMPLIFY-1 in adults without it, listed to start in December 2026 (NCT07881432).
What other amylin and incretin evidence is there?
Cagrilintide with semaglutide. REDEFINE 1 is the largest test of the idea: 3,417 adults with obesity or overweight and no diabetes, 68 weeks. Mean weight loss was 20.4% with the combination against 3.0% with placebo, and 14.9% and 11.5% with semaglutide alone and cagrilintide alone. Gastrointestinal events affected 79.6% of the combination group against 39.9% on placebo (Garvey et al., 2025). Our amylin and GLP-1 combinations article covers that programme.
Retatrutide with cagrilintide, in rats. This is the only published test of retatrutide with any amylin compound. In diet-induced obese male rats, the two together reduced body weight and food intake more than either alone, and more than matched pairings that used semaglutide or tirzepatide (Petersen et al., 2026). It is rodent evidence, in one sex, and cagrilintide is not eloralintide: cagrilintide is described as non-selective, eloralintide as selective for amylin receptors (Briere et al., 2025).
Is a four-receptor molecule the same thing?
No. On 4 November 2026, SCOHIA PHARMA and Celltrion described CT-G32 (SCO-940), one molecule designed to activate the GLP-1, GIP, glucagon and amylin receptors, at the TIDES Europe meeting (SCOHIA PHARMA, 4 November 2026). The data were preclinical, in diet-induced obese rats, with no figures in the release and no peer-reviewed paper. A single molecule has one fixed balance of receptor activity and one behaviour in the body. Two separate molecules mixed together do not, so its results say nothing about a blend. See our article on four-receptor peptides.
What is not known about the pair?
- Whether they interact. No study has measured how either compound behaves in the presence of the other.
- Tolerability together. Each causes gastrointestinal effects alone. Adding eloralintide to tirzepatide raised those effects and the share of people stopping treatment. Nobody has measured what happens with retatrutide.
- Any ratio. No trial has tested one. Lilly's trial of eloralintide with tirzepatide used several pairings and the results differed between them.
- Whether the effect adds up. The eloralintide with tirzepatide result came from adults with type 2 diabetes. Retatrutide's glucagon activity makes it a different partner from tirzepatide.
- Stability in one vial. There is no published compatibility or stability data for the two peptides mixed.
What is Retalora?
Retalora is Peptx's research blend of Retatrutide 10mg and Eloralintide 2.5mg in one lyophilised vial (12.5mg net), in UK Express stock and supplied as laboratory reference material. The ratio is a formulation choice. It is not taken from any clinical trial, because no trial of this pair exists, and none of the results above can be transferred to it. Two peptides in one vial is not a four-receptor molecule. See also our independent lab tests.
The bottom line
Adding amylin activity to incretin activity has real human evidence behind it: one phase 3 trial with cagrilintide and semaglutide, and one phase 2 trial with eloralintide and tirzepatide. Retatrutide with eloralintide has none. As of November 2026 the pair is an untested hypothesis, and the questions about interaction, tolerability and ratio are open.
References
- Billings LK, et al. (2025). Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet 406(10520):2631-2643. PubMed 41207310
- Briere DA, et al. (2025). Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Molecular Metabolism 102:102271. PubMed 41109426
- Coskun T, et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism 34(9):1234-1247.e9. PubMed 35985340
- Fischer SL, Borner T. (2026). Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs. Pharmacological Research 232:108382. PubMed 42586227
- Garvey WT, et al. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 393(7):635-647. PubMed 40544433
- Hay DL, et al. (2015). Amylin: Pharmacology, Physiology, and Clinical Potential. Pharmacological Reviews 67(3):564-600. PubMed 26071095
- Jastreboff AM, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine 389(6):514-526. PubMed 37366315
- Jastreboff AM, et al. (2026). Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine 395(18):1781-1793. PubMed 42814954
- Ludwig MQ, et al. (2026). A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance. Nature Metabolism 8(6):1350-1367. PubMed 42260119
- Petersen J, et al. (2026). Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats. Nature Metabolism 8(10):2069-2083. PubMed 42744908